Rituximab
Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients
SG Tylor
Source – ADC Therapeutics On July 20, 2023, ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...
ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes
SG Tylor
ABSTRACT NUMBER: 7506 Epcoritamab, a novel bispecific antibody targeting CD3 and CD20, has demonstrated potent T-cell-mediated cytotoxic activity against CD20-positive ...
